Skip to main content
. Author manuscript; available in PMC: 2018 Nov 7.
Published in final edited form as: Circulation. 2017 Jun 20;136(19):1863–1865. doi: 10.1161/CIRCULATIONAHA.117.029381

Figure 1. Overlap in eligibility for primary prevention with statin therapy based on trial evidence and ACC/AHA class I recommendations.

Figure 1

A: Area-proportional Venn diagrams demonstrating overlap in statin eligibility based on ACC/AHA class I recommendations (green) and evidence from randomized statin trials (blue). The percentages indicate the fraction of MESA participants aged 45 to 75 years who were eligible for statin therapy, or not eligible (below diagrams). B: Diagrams illustrating trials providing evidence for statin efficacy among ACC/AHA eligible individuals. Trial criteria were applied consecutively in chronological order clockwise starting 12 o'clock, that is, first we selected individuals according to WOSCOPS criteria (1995), then we selected additional individuals according to AFCAPS/TexCAPS criteria (1998), and so on.